Anticoagulant Reversal Drugs Market

Anticoagulant Reversal Drugs Market Size, Share, Growth Analysis, By Product Type(Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Regional(North America, Asia Pacific, Latin America) - Industry Forecast 2024-2031


Report ID: UCMIG35I2091 | Region: Global | Published Date: Upcoming |
Pages: 165 | Tables: 55 | Figures: 60

Anticoagulant Reversal Drugs Market Insights

Market Overview:

Anticoagulant reversal medicine sales were valued at USD 679.84 million globally in 2019; from 2020 to 2027, they are expected to increase at a CAGR of 14.3%. The approval and introduction of new medicines, the rising incidence of bleeding disorders, and the rise in the frequency of indications for anticoagulant medication are just a few of the factors that are driving the market. The U.S. FDA approved Andexxa by Portola Pharmaceuticals as the first factor Xa inhibitor antidote in May 2018, and its approval and release are important factors in the market growth for anticoagulants.

Anticoagulant Reversal Drugs Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
Get Free Sample

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Pharmaceuticals by segment aggregation, the contribution of the Pharmaceuticals in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The market for Anticoagulant Reversal Drugs was estimated to be valued at US$ XX Mn in 2021.

The Anticoagulant Reversal Drugs Market is estimated to grow at a CAGR of XX% by 2028.

The Anticoagulant Reversal Drugs Market is segmented on the basis of Product Type, Distribution Channel, Regional.

Based on region, the Anticoagulant Reversal Drugs Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the Anticoagulant Reversal Drugs Market are Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc., Octapharma AG, Dr. Reddy's Laboratories, AMAG Pharmaceuticals, Inc., Pfizer, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., Fresenius Kabi AG.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Anticoagulant Reversal Drugs Market

Report ID: UCMIG35I2091

$5,300
BUY NOW GET FREE SAMPLE